Vaccine Development

Study compares immune enhancers

Published in Vaccine Weekly, November 27th, 2002

A study published in the Proceedings of the National Academy of Sciences, USA, reported that Galenica Pharmaceuticals' immune enhancer or adjuvant GPI-0100 stimulated higher antibody titers in mice than the adjuvant QS-21.

The independent study was authored by scientists from the Memorial Sloan-Kettering Cancer Center, Laboratories of Tumor Vaccinology and Bioorganic Chemistry.

The paper addressed the development of novel synthetic multivalent vaccines containing different tumor-associated carbohydrate antigens, and compared the capacity of QS-21 and the related but stable and significantly less toxic GPI-0100 to enhance an antibody...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Vaccine Weekly

Source: Vaccine Weekly (2002-11-27)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry